Stock of the Day: Will Sangamo Biosciences, Inc. Short Squeeze Soon?

Stock of the Day: Will Sangamo Biosciences, Inc. Short Squeeze Soon?

The stock of Sangamo Biosciences, Inc. (NASDAQ:SGMO) hit a new 52-week low and has $3.07 target or 4.00% below today’s $3.20 share price. The 5 months bearish chart indicates high risk for the $222.52M company. The 1-year low was reported on Dec, 1 by Barchart.com. If the $3.07 price target is reached, the company will be worth $8.90 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. The stock last traded at $3.2 per share. It is down 49.21% since April 28, 2016 and is downtrending. It has underperformed by 55.13% the S&P500.

Analysts await Sangamo Biosciences, Inc. (NASDAQ:SGMO) to report earnings on February, 14. They expect $-0.25 earnings per share, down 25.00% or $0.05 from last year’s $-0.2 per share. After $-0.27 actual earnings per share reported by Sangamo Biosciences, Inc. for the previous quarter, Wall Street now forecasts -7.41% EPS growth.

Sangamo Biosciences, Inc. (NASDAQ:SGMO) Ratings Coverage

Out of 9 analysts covering Sangamo Biosciences (NASDAQ:SGMO), 4 rate it a “Buy”, 1 “Sell”, while 4 “Hold”. This means 44% are positive. Sangamo Biosciences has been the topic of 12 analyst reports since August 8, 2015 according to StockzIntelligence Inc. The rating was downgraded by Zacks to “Sell” on Tuesday, September 8. The rating was maintained by JP Morgan with “Buy” on Thursday, September 3. The company was maintained on Wednesday, September 2 by Wedbush. JP Morgan maintained Sangamo Biosciences, Inc. (NASDAQ:SGMO) rating on Saturday, August 8. JP Morgan has “Overweight” rating and $22 price target. The rating was initiated by Wells Fargo on Friday, December 4 with “Outperform”. The rating was downgraded by Janney Capital on Thursday, August 4 to “Neutral”. On Friday, October 23 the stock rating was reinitiated by Jefferies with “Buy”. On Friday, September 4 the stock rating was maintained by Cowen & Co with “Buy”. The stock of Sangamo Biosciences, Inc. (NASDAQ:SGMO) earned “Neutral” rating by Wedbush on Tuesday, November 1. The stock of Sangamo Biosciences, Inc. (NASDAQ:SGMO) has “Neutral” rating given on Wednesday, October 19 by Piper Jaffray.

According to Zacks Investment Research, “Sangamo BioSciences, Inc. is a leader in the development of novel transcription factors for the regulation of gene expression. Transcription factors are proteins that turn genes on or off by recognizing specific DNA sequences. The Universal Gene Recognition technology platform enables the engineering of a class of transcription factors known as zinc finger DNA binding proteins.”

Insitutional Activity: The institutional sentiment increased to 1.21 in 2016 Q2. Its up 0.40, from 0.81 in 2016Q1. The ratio increased, as 20 funds sold all Sangamo Biosciences, Inc. shares owned while 42 reduced positions. 13 funds bought stakes while 37 increased positions. They now own 45.72 million shares or 4.72% less from 47.99 million shares in 2016Q1.
First Republic Invest accumulated 0% or 19,500 shares. Hightower Advsr Ltd accumulated 30,605 shares or 0% of the stock. Franklin Street Advsrs Nc last reported 53,500 shares in the company. Price T Rowe Assoc Inc Md has invested 0% of its portfolio in Sangamo Biosciences, Inc. (NASDAQ:SGMO). Awm Inv Inc holds 92,200 shares or 0.11% of its portfolio. Capital Fincl Advisers Ltd Liability Company accumulated 32,214 shares or 0% of the stock. Bnp Paribas Arbitrage Sa last reported 0% of its portfolio in the stock. Voya Limited Liability Corp holds 1.18 million shares or 0.02% of its portfolio. Blackrock Incorporated holds 0% of its portfolio in Sangamo Biosciences, Inc. (NASDAQ:SGMO) for 6,797 shares. The New York-based Millennium Limited Liability has invested 0.01% in Sangamo Biosciences, Inc. (NASDAQ:SGMO). The Massachusetts-based Capital Impact Advsr Ltd Liability Co has invested 0.06% in Sangamo Biosciences, Inc. (NASDAQ:SGMO). Schwab Charles Inv Management Inc last reported 0% of its portfolio in the stock. Keybank National Association Oh owns 81,245 shares or 0% of their US portfolio. California State Teachers Retirement Sys holds 145,781 shares or 0% of its portfolio. Proshare Advsrs Ltd Liability Co has 60,971 shares for 0% of their US portfolio.

More notable recent Sangamo Biosciences, Inc. (NASDAQ:SGMO) news were published by: Streetinsider.com which released: “Sangamo Biosciences (SGMO) Appoints New Chief Medical Officer and Chief …” on December 01, 2016, also Fool.com with their article: “Why Sangamo Biosciences, Inc. Fell 29% Today” published on August 04, 2016, Prnewswire.com published: “Sangamo BioSciences Announces Participation At Upcoming Investor Conferences” on November 10, 2016. More interesting news about Sangamo Biosciences, Inc. (NASDAQ:SGMO) were released by: Prnewswire.com and their article: “Sangamo BioSciences Receives Orphan Drug Designation From The FDA For SB-FIX …” published on September 06, 2016 as well as Prnewswire.com‘s news article titled: “Sangamo BioSciences Announces New Gene Therapy Clinical Development Program …” with publication date: July 26, 2016.

SGMO Company Profile

Sangamo Biosciences Inc., incorporated on June 22, 1995, is a clinical-stage biopharmaceutical company. The Firm is focused on the research, development and commercialization of engineered deoxyribonucleic acid (DNA)-binding proteins for therapeutic genome editing and gene regulation. The Firm is engaged in developing zinc finger DNA-binding proteins (ZFP) therapeutics, which are therapeutic products for the treatment of genetic disease. The Company’s ZFP Therapeutic, SB-728, a ZFP nuclease (ZFN)-modified autologous cell product for the treatment of Human immunodeficiency virus infection and acquired immune deficiency syndrome (HIV/AIDS), is the therapeutic application of its ZFN genome editing technology and is being evaluated in an ongoing Phase II study of ZFN-modified T-cells (SB-728-T-1101, Cohort 3) and a Phase I/II study of modified hematopoietic stem cells (SB-728mR-HSPC) in HIV-infected subjects. The Firm has preclinical programs in hemophilia A and other Lysergic acid diethylamide (LSDs), and research stage programs in other monogenic diseases, including certain central nervous system (CNS) disorders and cancer immunotherapy.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment